Risk of impairment of fixed assets due to declining profitability
First written in FY2016. 12 of 20 entries say "Mitigated", first in FY2020-Q1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MitigatedAnnual report
「Consolidated fiscal year (1 April 2024 to 31 March 2025): Not applicable.」
The company did not record an impairment loss in the current period, and fixed-asset impairment due to declining profitability, which amounted to ¥602,000 in the previous year, no longer occurred. - FY2025-H1MitigatedAnnual report
「Impairment loss 602 ―」
The impairment loss of ¥602,000 recorded in the same period of the previous year was not recorded in the six-month interim consolidated period. - FY2024-Q2MitigatedAnnual report
「Impairment loss 804 602」
The impairment loss decreased from ¥804,000 in the same period of the previous year to ¥602,000, reducing the scale of fixed-asset impairment due to declining profitability. However, an impairment loss still occurred during the current period. - FY2024-Q1MitigatedAnnual report
「Impairment loss 804 602」
The impairment loss decreased from ¥804,000 in the same period of the previous year to ¥602,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2023MitigatedAnnual report
「The company recorded an impairment loss of ¥804,000 during the consolidated fiscal year.」
Although fixed-asset impairment occurred, it decreased from ¥7.041 million in the previous year to ¥804,000, reducing in scale. - FY2023-Q2MitigatedAnnual report
「Impairment loss 7,041 804」
The impairment loss decreased from ¥7.041 million in the same period of the previous year to ¥804,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2023-Q1MitigatedAnnual report
「Impairment loss 7,041 804」
The impairment loss decreased from ¥7.041 million in the same period of the previous year to ¥804,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2022-Q2WorsenedAnnual report
「Impairment loss 118 7,041」
The impairment loss increased from ¥118,000 in the same period of the previous year to ¥7.041 million, expanding the scale of fixed-asset impairment due to declining profitability. - FY2022-Q1WorsenedAnnual report
「Impairment loss 118 7,041」
The impairment loss increased from ¥118,000 in the same period of the previous year to ¥7.041 million, expanding the scale of fixed-asset impairment due to declining profitability. - FY2021-Q3MitigatedAnnual report
「Impairment loss 237 118」
The impairment loss decreased from ¥237,000 in the same period of the previous year to ¥118,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2021-Q1MitigatedAnnual report
「Impairment loss 237 118」
The impairment loss decreased from ¥237,000 in the same period of the previous year to ¥118,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2020MitigatedAnnual report
「The company recorded an impairment loss of ¥237,000 during the consolidated fiscal year.」
The impairment loss decreased from ¥8.255 million in the previous fiscal year to ¥237,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2020-Q2MitigatedAnnual report
「Impairment loss 8,255 237」
The impairment loss decreased from ¥8.255 million in the same period of the previous year to ¥237,000, reducing the scale of fixed-asset impairment due to declining profitability. - FY2020-Q1MitigatedAnnual report
「Impairment loss 8,255 237」
The impairment loss for the current quarter was ¥237,000, down from ¥8.255 million in the same period of the previous year. Impairment due to declining profitability continued to occur, but was smaller than in the same period of the previous year. - FY2019WorsenedAnnual report
「The company recorded an impairment loss of ¥8.255 million during the consolidated fiscal year.」
The company recorded impairment losses totaling ¥8.255 million, comprising ¥235,000 on land used in the Diagnostics and Reagents business and ¥8.019 million on land used in the Genetically Modified Silkworms business, up from ¥576,000 in the previous year. - FY2019-Q1WorsenedAnnual report
「Impairment loss 8,255」
Due to the decline in the appraised value of land held and other factors, the impairment loss for the first quarter was ¥8.255 million, up from ¥576,000 in the same period of the previous year. - FY2018MaterialisedAnnual report
「The company recorded an impairment loss of ¥576,000 during the consolidated fiscal year.」
The company recorded an impairment loss of ¥576,000 on land used in the Diagnostics and Reagents business, having determined that neither profitability nor market value was expected to recover. - FY2018-Q1MaterialisedAnnual report
「Impairment loss: ¥576,000」
The company recorded an impairment loss of ¥576,000 in the first quarter, marking the recurrence of fixed-asset impairment due to declining profitability. - FY2017WorsenedAnnual report
「Given the high uncertainty surrounding future earnings at this stage due to the nature of the Group's business, the Group reviewed profitability across the company, reduced the carrying amounts of assets to their recoverable amounts, and recorded the resulting reduction of ¥735.395 million as an impairment loss.」
The impairment loss increased from ¥1.852 million in the previous fiscal year to ¥735.395 million, arising in the Diagnostics and Reagents, Genetically Modified Silkworms, Testing, and Cosmetics segments. - FY2016First statedAnnual report
「If the profitability of the company or any Group company declines significantly, it may become necessary to record impairment losses on land, buildings, goodwill and other assets held by the company or Group companies. This could affect the Group's operating performance and financial position.」
The company recorded an impairment loss of ¥1.852 million for Neo Silk Cosmetics because the originally anticipated earnings could no longer be expected.